PTGX - CIK 0001377121
Protagonist Therapeutics, Inc (PTGX) reported revenue of $46.02M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $46.02M | -89.4% |
| FY 2024 | $434.43M | +624.1% |
| FY 2023 | $60.00M | +125.7% |
| FY 2022 | $26.58M | -2.8% |
| FY 2021 | $27.36M | -4.4% |
| FY 2020 | $28.63M | +12293.1% |
| FY 2019 | $231.00K | -99.3% |
| FY 2018 | $30.93M | +54.1% |
| FY 2017 |
Protagonist Therapeutics, Inc (PTGX) reported revenue of $46.02M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2017 and fiscal 2025, Protagonist Therapeutics, Inc's revenue grew from $20.06M to $46.02M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $20.06M |
| - |